
CAMP4 Therapeutics Corporation: updates and filings
Price
$3.79
November 20, 2026Market cap $299M
What Ploutos Investor adds for CAMP4 Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 3 fiscal years, from 2023
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Aug 13, 2026next Feb 5, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
August 2026
May 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 12, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Nov 5, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 5, 2026Financial statements and exhibitsForm8-K
- Nov 5, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Sep 28, 2026Regulation FD disclosure, other material eventsForm8-K
- Aug 31, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Aug 19, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 13, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 13, 2026Results of operationsForm8-K
- Aug 12, 2026FilingFormEFFECT
- Aug 10, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Aug 6, 2026Shelf registration for future offeringsFormS-3
- Aug 5, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Aug 4, 2026Material agreement entered, unregistered sale of shares, Regulation FD disclosureForm8-K
- Jul 27, 2026Regulation FD disclosure, other material eventsForm8-K
- Jun 12, 2026Officer or director change, shareholder voteForm8-K
- May 15, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- May 14, 2026Regulation FD disclosureForm8-K
- May 7, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 7, 2026Results of operationsForm8-K
- Apr 23, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 23, 2026Additional annual meeting materialFormDEFA14A
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 12, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Nov 5, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 5, 2026 | 8-K | Financial statements and exhibits | Document |
| Nov 5, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Sep 28, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Aug 31, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Aug 19, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 13, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 13, 2026 | 8-K | Results of operations | Document |
| Aug 12, 2026 | EFFECT | Filing | Document |
| Aug 10, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Aug 6, 2026 | S-3 | Shelf registration for future offerings | Document |
| Aug 5, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Aug 4, 2026 | 8-K | Material agreement entered, unregistered sale of shares, Regulation FD disclosure | Document |
| Jul 27, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Jun 12, 2026 | 8-K | Officer or director change, shareholder vote | Document |
| May 15, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| May 14, 2026 | 8-K | Regulation FD disclosure | Document |
| May 7, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 7, 2026 | 8-K | Results of operations | Document |
| Apr 23, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 23, 2026 | DEFA14A | Additional annual meeting material | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Sep 25, 2018.
The full analysis
What do CAMP4 Therapeutics's filings show?
The filings are where every one of CAMP4 Therapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.